Specify a stock or a cryptocurrency in the search bar to get a summary
Avenue Therapeutics Inc
ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida. Address: 1140 Avenue of the America, New York, NY, United States, 10036
Analytics
WallStreet Target Price
32 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ATXI
Dividend Analytics ATXI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATXI
Stock Valuation ATXI
Financials ATXI
Results | 2019 | Dynamics |